Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
We’ve had to make this difficult decision in order to protect vital NHS services and also to test ways of delivering this new ...
18hOpinion
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...
Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound. Here's how we reported it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback